AUTHORS
Naszrin Arani, MD, Sanam Loghavi, MD2, Courtney DiNardo, MD, MSCE3, Gautam Borthakur, MD4, Tapan Kadia I, MD5, Elias Jabbour, MD6, Nicholas Short, MD7, Wei Ying Jen, BM BCh, FRCPath8, Abhishek Maiti, MBBS9, Hussein Ali Abbas, MD, PhD10, Ghayas C. Issa, MD11, Jennifer Marvin-Peek, MD12, Fadi G. Haddad, MD13, Guillermo Montalban-Bravo, MD14, Uday Popat, MD, MBA15, Elizabeth Shpall, MD16, Hagop Kantarjian, MD17, Guillermo Garcia-Manero, MD18, Naval Daver, MD19, Jayastu Senapati, MBBS, MD, DM20
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, United States
16 The University of Texas MD Anderson Cancer Center, Houston, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
20 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
BACKGROUND:
Outcomes of patients (pts) with ND AML with myelodysplasia-related gene mutations (MRMs), while traditionally adverse, appear to be better with LIT regimens + venetoclax (VEN). The impact of these MRMs as a measurable residual disease (MRD) marker, however, warrants further investigation.
METHODS:
We retrospectively analyzed the impact of persistence/clearance of MRM at best response of CR/CRi, in pts with LIT+VEN treated ND AML (with available genomic data), treated at our institution between 2017 - 2025 who had ≥1 MRM (ASXL1, BCOR, EZH2, STAG2, SF3B1, SRSF2, U2AF1, and/or ZRSR2) and/or RUNX1 mutation (mut) at diagnosis, at a VAF cutoff of ≥2%. Pts with CBF-AML, APL, or treated secondary AML were excluded. MRM dynamics were tracked at baseline and at time of best response (CR/CRi) and correlated with relapse free/overall survival (RFS/OS) outcomes.
RESULTS:
A total of 186 pts, median (med) age 71 yrs (range, 56-87 yrs), were included; 96% were ≥ 60 yrs. The common baseline MRM were SRSF2 (51%), RUNX1 (35%), ASXL1 (30%), and STAG2 (16%). Overall, 17% had concurrent NPM1 mut, 10% FLT3-ITD (AR>0.05), 19% RAS, 8% TP53. 15% had complex cytogenetics; 62%, 30%, and 8% had ELN 2024 favorable, intermediate, and adverse-risk genetics, respectively. In this cohort 109 (58%) received hypomethylating agent based and the rest (42%) cladribine/low-dose cytarabine based LIT. Overall, 150 (81%) achieved CR and 36 (19%) CRi. 120/169 (71%) pts with available data achieved MRD negative (-) status by flow cytometry (FCM; <0.01%) at CR/CRi. At CR/CRi, 51 (27%) cleared their MRMs (MRM-) while 135 (73%) retained MRMs (MRM+); among pts who achieved FCM MRD- CR/CRi, 36/120 (30%) were MRM- and 84/120 (70%) MRM+. 10/49 (20%) FCM MRD+ pts were MRM-. Med cycle to CR/CRi was 1.
Pts who cleared MRMs at CR/CRi had superior med RFS (24 [95% CI 15-NR] vs. 14 mos [10-19], p=0.02) and OS (54 [23-NR] vs. 24 mos [17-32], p=0.03) compared to MRM+ pts. Among the 120 FCM MRD- pts, the med RFS (25 vs. 17 mos [18-NR], p=0.02) and med OS (NR vs. 24 mos [15-40], p=0.02) was still significantly superior among MRM- (n=36) versus MRM+ (n=84) pts. 72 pts (39%) underwent a hematopoietic stem cell transplantation (HSCT) in CR1, 29/72 (40%) MRM- and 43/72 (60%) MRM+; in the overall cohort MRM+ pts were less likely to undergo HSCT than MRM- (OR .4 [.2-.7], p=.002). Among FCM MRD- pts who did not undergo HSCT, OS (NR vs. 19 mo [15-37], p=0.04) was better in MRM- pts (n=15) versus MRM+ pts (n=56). Pts who cleared spliceosome factor (SF) muts (SF3B1, SRSF2, U2AF1, and/or ZRSR2) (n= 86) at CR/CRi had superior RFS (21 vs. 14 mo [15-33], p=.04) and OS (33 vs. 24 [14-34], p=.04) compared to those who retained SF muts at CR/CRi (n=100). Pts who cleared DNMT3A, ASXL1, TET2 muts had comparable RFS (20 vs. 16 mo [10-49], p=.26) and OS (32 vs. 25 mo [19-68], p=.37) compared to those who retained them at CR/CRi (n=110). Finally, on Cox MVA, clearance of MRMs at CR/CRi was independently associated with favorable OS (HR=0.45, 95% CI 0.24-0.79, p=0.004), along with DDX41, IDH1, IDH2, and BCOR muts, while TP53 and RAS mut were unfavorable.
CONCLUSION:
In our analysis, the status of MRM clearance at CR/CRi in AML treated with LIT+VEN with baseline MRM affected survival outcomes, including in pts FCM MRD- at CR/CRi.
DISCLOSURES
Naszrin Arani, MD: Abbvie - Honoraria; Abbvie - Consultancy (Includes expert testimony)